M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Pharmaceutical TechnologyRegeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.Read full story pharminent May 19, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: SCOTUS won’t hear pharma’s IRA complaintsNext: VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
